Hematol Oncol. 2020 Sep 2. doi: 10.1002/hon.2796. Online ahead of print.
Nivolumab is approved for relapsed/refractory Classical Hodgkin Lymphoma (r/rCHL). Whether nivolumab may be used as a bridge to autologous stem cell transplantation (ASCT) is not accurately investigate. We report a series of five cases of CHL chemorefractory to several lines of salvage therapy treated with nivolumab monotherapy and ASCT. Following ASCT, four patients achieved complete response (CR) and one remained with indeterminate FDG-avid lesions by PET/CT. All patients are in CR at last
follow-up with a median duration of response of 36.4 months. No patient has received post-ASCT treatment. ASCT in chemorefractory CHL responding to nivolumab therapy may yield sustainable remission in this high-risk population. This article is protected by copyright. All rights reserved.